Member Info for Surprised2

Or is it so early I’m still dreaming ??

Like an English plate of fish and chips Rene sadly continues to promise more than it delivers. Hopefully this will change in ‘21 or ‘22

A dollar I guess is about 75p. So whether the trend line bottoms out at that, 87p or wherever, it’s not going to make a lot of difference in the grand scheme of things, unless of course someone is looking to make a fast buck! Sadly for those of us who’ve been around a while and who are hoping for all (or nothing) we’re subject to the vagaries of the Board and it’s strategy for raising cash and achieving outcomes. The latter often seem to be driven by, “it’ll take as long as it takes”! Have a good Sunday.

As we wake up to warm clear skies, sadly and stating the obvious, we’re going to loiter around a buck a share until we raise cash or something magical happens. The latter unfortunately is presently well hidden.

Hysteria breaks out following rumors that Rene is changing it’s janitor?
One regular board pundit confidently boasted, “this is definitely a sign we’re going to clean up!”

As we consider what next; interpreting rationed news flows from our Board I wonder from afar whether Freddie has returned? Perhaps reincarnated into another form. Just an early morning thought that probably has little or no substance - not unlike many of my posts!

Despite some posters‘ mathematical projections that Rene has sufficient cash to last a year they won’t run it down to the last buck so there’ll be a cash call. The question you ask GB is when, unfortunately Rene appear to be quickly running out of options. Let’s hope they’ve some magic solution that won’t cause further dilution. Oh for a detailed business plan, which showed more than simply research time lines. Funding will however demand such information, sadly we may not see it; certainly in the first instance!

Another Reneuron week where crystal balls were clearly not polished enough and predictions once again fell to the wayside. Perhaps next ...we’ll know soon enough though and hopefully it will be good news.

My limited understanding of U.K. law is 21 days notice for an AGM but I may be wrong or maybe I’ve missed the notification. Perhaps they’re concluding something, which they wish to announce alongside the results, thus the delay - personally like many I’ve no clue. Have a good weekend.

A Fosun stage payment wouldn’t ‘cause’ a dilution - it may help to prevent one if it mitigates some future cash call. Too early in the morning - apologies

I would concur with GBs assessment of the role of exosome collaborations, and whilst I haven’t sight of the criteria for Fosun’s stage payments, any injection of cash would be welcome not least if it doesn’t cause dilution! It would be disappointing to have come so far, only to find potential retail shareholder value halved. Hopefully however, as others have suggested, the AGM will soon provide information, which removes the need for our extrapolations.

I agree, it’s a totally prudent move in the circumstances.

The reality of diminishing cash, but as others have stated lets hope Hunt has something else up his sleeve not least moving from dollar burn to dollar generation!

There’s seems to be a suggestion in calculating Rene’s forward cash position that the business will run cash down to the final dollar (or there’ll be additional income streams, some of which are yet unknown, certainly to retail investors).
Can those who’s records or memories stretch back to 2015 recall what Rene’s cash position represented at the time of the last cash call. Was it equivalent of six or twelve months projected expenditure? Thank you.

The latest RNS provides another interesting insight into this small $15m/a UK business; its global reach. We’re familiar with Fosun, the US trials, as well as yet unknown collaborations, but this research paper takes Rene to South Korea.
The if and when are still unknown but we’re starting to see reliable world-wide data, which will only increase through time, including through Fosun’s future trials.
That data will hopefully confirm the potential for novel therapies. Therapies, which in a world where buyers, particularly state actors, are becoming increasingly discerning, could be charged on a payment by results basis.
Thus for Big Pharma where low research productivity is not uncommon, potentially ready-made, global, commercially viable novel therapies, for what are devastating diseases, must become of interest … surely?

As many of us stare out of City windows the recent news and share price respite is welcome. But I'm sure many of us would also like to understand the company's forward cash position resulting from these collaborations, some of which are now twelve months old.
Is this recent RNS predicated on marginal cost recovery i.e. cents or does it provide for a contribution to sunk research/development costs? When does the company expect, all things being equal, to see end players buying or licensing products, which in itself may trigger third party interest.
Rene seems to simply flirt with its shareholders, certainly of the retail variety!

Will be interesting to see, given understandable delays and what appears to be still an early stage in the Fosun project, which may impact some assumptions on anticipated benefits, when a cash call will be made and the form it will take.

Unfortunately none of us knows gb so most posts are pure speculation, as mine most certainly was. But I appreciate that fun is had by fantasising about RENE’s potential and prospects. It is just that but nevertheless, I like most, hope it’s realised but who knows; I certainly don’t and I’m not going to kid myself or others by thinking that I do.

I would expect that the receipt of $8m would trigger an immediate RNS given Rene’s eroding cash position.

Putting aside an announcement however, given the fanfare, and the apparent materiality of this deal I’m sure many are disappointed that Fosun progress updates are not included in any of Hunt and co’s ‘boiler plate’ presentations. Is it going to plan or is it going pear shaped ....

As Chester publicly wrestles with his dilemma, I ponder on why Rene has still to receive, some twelve months after the fanfare, its first ‘near term operational milestone’ tranche of $7.9m from Fosun! Twelve months on $104.8m seems ... who knows ...?